BRVE
Braveheart Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.19
−2.62%Next report
Analyst consensus
- Next report date
- Dec 8, 2026
- EPS estimate
- -$0.91
- Revenue estimate
- —
Latest reported
- Last report date
- Sep 8, 2026
- EPS actual
- -$2.51
- EPS estimate
- $2.69
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -193.3%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 8, 2026 | $2.69 | -$2.51 | Miss -193.31% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 8, 2026